Pacira BioSciences stock slides nearly 10% after preliminary Q4 revenues of $196.9 million miss estimates, despite Exparel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback